Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 3Mesothelioma 3Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Thymoma 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Medical Oncology 1Fallopian Tube Endometrioid Adenocarcinoma 1Cholangiocarcinoma 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms × anetumab ravtansine × Clear all
NCT03102320 2022-06-30

ARCS-Multi

Bayer

Phase 1 Completed
173 enrolled
BreastGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Thymoma, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT02696642 2021-07-09

Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment

Bayer

Phase 1 Completed
54 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡